Relmada Therapeutics, Inc. Analyst EPS Estimates
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 0 | -$0.83 | -$0.83 | -$0.83 |
Q2 2024 | 2 | -$0.72 | -$0.53 | -$0.63 |
Q3 2024 | 0 | -$0.63 | -$0.63 | -$0.63 |
Q1 2025 | 1 | -$0.63 | -$0.63 | -$0.63 |
Q2 2025 | 1 | -$0.75 | -$0.75 | -$0.75 |
Q3 2025 | 1 | -$0.89 | -$0.89 | -$0.89 |
Q4 2025 | 1 | -$1.02 | -$1.02 | -$1.02 |
Relmada Therapeutics, Inc. Earnings Date And Information
Relmada Therapeutics, Inc. last posted its earnings results on Wednesday, August 7th, 2024. The company reported $-0.59 earnings per share for the quarter, topping analysts' consensus estimates of $-0.83 by $0.24. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Relmada Therapeutics, Inc. has generated $-3 earnings per share over the last year ($-3.28 diluted earnings per share) and currently has a price-to-earnings ratio of -1.13. Relmada Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 5th, 2024 based on prior year's report dates.
Relmada Therapeutics, Inc. Earnings History by Quarter
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
08/07/2024 | Q2 2024 | -$0.83 | -$0.59 | 0.24 | $0 | $0 |
05/08/2024 | Q1 2024 | -$0.90 | -$0.72 | 0.18 | $0 | |
03/19/2024 | Q4 2023 | -$0.88 | -$0.84 | 0.04 | $0 | |
11/08/2023 | Q3 2023 | -$0.95 | -$0.73 | 0.22 | $0 | |
08/08/2023 | Q2 2023 | -$0.92 | -$0.84 | 0.08 | $0 | |
05/11/2023 | Q1 2023 | -$0.88 | -$0.87 | 0.01 | $0 | |
03/23/2023 | Q4 2022 | -$1.26 | $0 | |||
11/10/2022 | Q3 2022 | -$1.40 | -$1.31 | 0.09 | $0 | |
08/11/2022 | Q2 2022 | -$1.30 | -$1.33 | -0.03 | $0 | |
05/05/2022 | Q1 2022 | -$1.21 | -$1.40 | -0.19 | $0 | |
03/25/2022 | Q4 2021 | -$1.80 | $0 | |||
11/12/2021 | Q3 2021 | -$2.44 | $0 | |||
08/10/2021 | Q2 2021 | -$1.47 | -$1.56 | -0.09 | $0 | |
05/12/2021 | Q1 2021 | -$1.39 | -$1.34 | 0.05 | $0 | |
03/24/2021 | Q4 2020 | -$1.28 | $0 | |||
11/12/2020 | Q3 2020 | -$0.86 | -$1.05 | -0.19 | $0 | |
08/12/2020 | Q2 2020 | -$0.55 | -$0.73 | -0.18 | $0 | |
05/15/2020 | Q1 2020 | -$0.33 | -$0.72 | -0.39 | $0 | |
12/30/2019 | Q4 2019 | -$0.40 | $0 | |||
11/13/2019 | Q3 2019 | -$0.38 | $0 |
Relmada Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Relmada Therapeutics, Inc.'s earnings date?
Relmada Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 5th, 2024 based off last year's report dates.
-
Did Relmada Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Relmada Therapeutics, Inc. (:RLMD) reported $-0.59 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.83 by $0.24.
-
How can I listen to Relmada Therapeutics, Inc.'s earnings conference call?
The conference call for Relmada Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Relmada Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Relmada Therapeutics, Inc.'s latest earnings report can be read online.
-
How much profit does Relmada Therapeutics, Inc. generate each year?
Relmada Therapeutics, Inc. (:RLMD) has a recorded net income of $0. Relmada Therapeutics, Inc. has generated $-3.28 earnings per share over the last four quarters.
-
What is Relmada Therapeutics, Inc.'s price-to-earnings ratio?
Relmada Therapeutics, Inc. (:RLMD) has a price-to-earnings ratio of -1.13 and price/earnings-to-growth ratio is -0.03.